KASTELEIN JOHANNES JACOB PIETER (Chief Scientific Officer) sold 64.3% of their position (125K shares) of NEWAMSTERDAM PHARMA CO N.V. on the open market
Open‑market sale worth $3.36M — a major position exit. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 8/25/2026ACC: 0001193125-26-365202
DirectorOfficer· Chief Scientific Officer
Since Mar 2026
-125K
Net shares
Net seller
$3.36M
Total sold
1
Open market trades
0B · 1S
3
Total transactions
125K acquired · 250K disposed
Non-Derivative Transactions2
Ordinary Shares
Indirect
Shares
+125K
Price / share
—
Trade value
—
% of position
180.4%
8/24/2026
69.30K→194.30K
Ordinary Shares
Indirect
Shares
−125K
Price / share
$26.91
Trade value
$3.36M
% of position
64.3%
8/24/2026
194.30K→69.30K
Total
Net shares
+0.00
Net value
-$3.36M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Indirect | 8/24/2026 | M · Option Exercise | +125K | — | — | 180.4% | 69.30K | 194.30K |
| Ordinary Shares Indirect | 8/24/2026 | S · Sale | −125K | $26.91 | $3.36M | 64.3% | 194.30K | 69.30K |
| Total | +0.00 | -$3.36M | ||||||
Derivative Transactions1
Option (right to buy)
Indirect
Converts to
Ordinary Shares
125K shares
Shares
−125K
Strike price
Held after
395.23K
Exercisable
—
8/24/2026
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Option (right to buy) Indirect | Ordinary Shares125K shares | 8/24/2026 | M · Option Exercise | −125K | — | 395.23K |
Non-Derivative Holdings (Post-Transaction)1
Ordinary Shares
DirectShares owned53.50K
Total
53.50K direct53.50K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Ordinary Shares | 53.50K | Direct |
| Total | 53.50K | 53.50K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported